Robert Azelby has served as a member of ADC Therapeutics' board of directors since June 2023. From October 2020 to February 2023 he was President and Chief Executive Officer of Eliem Therapeutics, and previously Chief Executive Officer of Alder BioPharmaceuticals until its 2019 acquisition by H. Lundbeck, and Executive Vice President, Chief Commercial Officer of Juno Therapeutics; earlier he held various positions at Amgen, including vice president and general manager, oncology. He currently serves on the boards of Autolus Therapeutics, Cardinal Health and Terns Pharmaceuticals. Mr. Azelby holds a B.A. in Economics and Religious Studies from the University of Virginia and an M.B.A. from Harvard Business School.